The global nanomedicine market is anticipated to reach USD
350.8 billion by 2025, according to a new report by Grand View Research, Inc.
Development of novel nanotechnology-based drugs and therapies is driven by the
need to develop therapies that have fewer side effects and that are more
cost-effective than traditional therapies, in particular for cancer.
Application of
nanotechnology-based contrast reagents for diagnosis and monitoring of the
effects of drugs on an unprecedented short timescale is also attributive drive
growth in the coming years. Additionally, demand for biodegradable implants
with longer lifetimes that enable tissue restoration is anticipated to
influence demand.
As per the WHO factsheet, cancer
is found to be one of the major causes of mortality and morbidity worldwide,
with approximately 14 million new cases in 2012 and 8.2 million cancer-related
deaths. Thus, demand for nanomedicine in order to curb such high incidence rate
is expected to boost market progress during the forecast period.
Solutions such as
nanoformulations with triggered release for tailor-made pharmacokinetics,
nanoparticles for local control of tumor in combination with radiotherapy, and
functionalized nanoparticles for targeted in-vivo activation of stem cell
production are anticipated to drive R&D, consequently resulting in revenue
generation in the coming years.
Biopharmaceutical and medical
devices companies are actively engaged in development of novel products as
demonstrated by the increasingly growing partnerships between leading
enterprises and nanomedicine startups. For instance, in November 2015, Ablynx
and Novo Nordisk signed a global collaboration and a licensing agreement for
development and discovery of innovative drugs with multi-specific nanobodies.
This strategic partnership is anticipated to rise the net annual sales of the
products uplifting the market growth.
However, in contrary with the
applications of nanotechnology, the entire process of lab to market approval is
a tedious and expensive one with stringent regulatory evaluation involved
thereby leading investors to remain hesitant for investments.
Browse full research report on Nanomedicine Market: http://www.grandviewresearch.com/industry-analysis/nanomedicine-market
Further key findings from
the report suggest:
- Therapeutics accounted for the largest share of
market revenue in 2016 owing to presence of nanoemulsions,
nanoformulations, or nanodevices
- These devices possess the ability to cross biological
barriers. Moreover, presence of drugs such as Doxil, Abraxane, and Emend
is attributive for higher revenue generation
- Presence of substantial number of products
manufactured through the use of microbial sources can be attributed for
the largest share
- In-vitro diagnostics is expected to
witness lucrative progress as a result of R&D carried out in this
segment
- Introduction of nano-enabled biomarkers, vectors and
contrast agents with high-specificity and sensitivity are attributive for
projected progress
- Clinical cardiology is expected to witness the
fastest growth through to 2025 owing to development in
nano-functionalization and modification of surfaces for increased
biocompatibility of implants in treatment of late thrombosis
- Moreover, an abundance of research publications and
patent filings from European region with a share of about 25% in
nanomedicine-related publications is supportive for revenue generation
from European economies
- Asia Pacific is estimated to witness the fastest
growth over the forecast period
- Factors responsible include government and regulatory
authorities that have implemented a framework to encourage R&D
collaborations and framework extension.
- Key players operating in this industry include Pfizer
Inc., Ablynx NV, Nanotherapeutics Inc., Nanoviricides Inc., Abraxis Inc.,
Arrowhead Research Inc., Celgene Corporation, Bio-Gate AG, and Merck
- Active expansion strategies are undertaken by a
number of the major market entities in order to strengthen their position
- North America dominated the industry in 2016,
accounting for a 42% of total revenue
- Presence of key participants operating in the region
are involved in collaborative activities are attributive for the largest
share of North America in sector revenue
Browse more reports of this category by Grand View
Research: http://www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the nanomedicine market on
the basis of product, application, nanomolecule type, and region:
Nanomedicine Product Outlook (Revenue, USD Billion;
2013 - 2025)
- Therapeutics
- Regenerative
medicine
- In-vitro
diagnostics
- In-vivo
diagnostics
- Vaccines
Nanomedicine Application Outlook (Revenue, USD Billion;
2013 - 2025)
- Clinical
Oncology
- Infectious
diseases
- Clinical
Cardiology
- Orthopedics
- Others
Nanomedicine Nanomolecule Type Outlook (Revenue, USD
Billion; 2013 - 2025)
- Nanoparticles
- Metal
& Metal Oxide Nanoparticles
- By
Type
- Gold
Nanoparticles
- Silver
Nanoparticles
- Iron
Oxide Nanoparticles
- Alumina
Nanoparticles
- Gadolinium
Oxide Nanoparticles
- Others
- By
Application
- In-vivo Imaging
- Targeted
Drug Delivery
- Proton
Therapy
- In-vitro
assays
- Cell
& Phantom Imaging
- Liposomes
- Polymers
& polymer drug conjugates
- Hydrogel
nanoparticles
- Dendrimers
- Inorganic
nanoparticles
- Nanoshells
- Nanotubes
- Nanodevices
Nanomedicine Regional Outlook (Revenue, USD Billion; 2013
- 2025)
- North
America
- U.S.
- Canada
- Europe
- Germany
- UK
- Asia
Pacific
- Japan
- China
- Latin
America
- Brazil
- Middle
East and Africa (MEA)
- South
Africa
About Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides
syndicated research reports, customized research reports, and consulting
services. To help clients make informed business decisions, we offer market
intelligence studies ensuring relevant and fact-based research across a range
of industries, from technology to chemicals, materials and healthcare.
No comments:
Post a Comment